Case Report
 
Complete remission in an elderly patient of advanced-stage squamous cell carcinoma lung with nivolumab: An exceptional case study from India
Shyam Aggarwal1, Sachin Minhas1, Shrinivas Shinde1, Madhusudan Ganvir1
1Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India

Article ID: Z01201801CR10877SA
doi:10.5348/ijcri-201808-CR-10877

Corresponding Author:
Dr. Sachin Minhas,
Department of Medical Oncology,
Sir Ganga Ram Hospital,
New Delhi 110060,
India

Access full text article on other devices

  Access PDF of article on other devices

[Abstract HTML]   [Full Text HTML]   [Full Text PDF]   [Print This Article]
[Similar article in Pumed] [Similar article in Google Scholar]


How to cite this article
Aggarwal S, Minhas S, Shinde S, Ganvir M. Complete remission in an elderly patient of advanced-stage squamous cell carcinoma lung with nivolumab: An exceptional case study from India. Int J Case Rep Images 2018;9(1):51–55.


ABSTRACT

Introduction: Recent research of immunotherapy on non-small cell lung cancer (NSCLC) has initiated a change in the management of this disease with offering a potential for prolonged responses and survival. However, the treatment options for advanced stage lung squamous cell carcinoma (SCC) remain limited. In recent times a fully human IgG4 programmed death one immune checkpoint inhibitor antibody nivolumab was approved by Drug Controller General of India to treat patients with advanced stage, relapsed or refractory lung SCC.
Case Report: In this case report, we have discussed about an elderly patient of NSCLC who showed complete remission with nivolumab in short duration of treatment without any significant adverse event. To date, this is the first case of complete remission in relapsed advanced stage SCC lung with nivolumab in India and contributes to the exceptional cases of nivolumab in SCC in the world.
Conclusion: This report suggests exceptional safety and efficacy of nivolumab in elderly patients with NSCLC. Further research in larger sample size in Asian countries is needed to test the safety and efficacy of nivolumab immunotherapy for elderly patients with NSCLC.

Keywords: Immunotherapy, Lung squamous cell carcinoma, Nivolumab, Oncology, PD-L1


[Abstract HTML]   [Full Text HTML]   [Full Text PDF]

Author Contributions
Shyam Aggarwal – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Sachin Minhas – Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Shrinivas Shinde – Acquisition of data, Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Madhusudan Ganvir – Acquisition of data, Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guarantor of Submission
The corresponding author is the guarantor of submission.
Source of Support
None
Conflict of Interest
Authors declare no conflict of interest.
Copyright
© 2018 Shyam Aggarwal et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.